1. Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
   Judith Raimbourg et al, 2017, Molecular Cancer Therapeutics CrossRef
2. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
   Madusha Meemanage et al, 2021, Cancer Chemotherapy and Pharmacology CrossRef
3. Esophageal squamous cell carcinoma invasion is inhibited by Activin A in ACVRIB-positive cells
   Holli A. Loomans et al, 2016, BMC Cancer CrossRef
4. Epidermal growth factor receptor (EGFR)—MAPK—nuclear factor(NF)‐κB—IL8: A possible mechanism of particulate matter(PM) 2.5‐induced lung toxicity
   Seung‐Chan Jeong et al, 2017, Environmental Toxicology CrossRef
5. Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway
   Jiajia Gu et al, 2016, Biochemistry Research International CrossRef
6. Molecular profiles in foregut oncology
   Prashant Sukharamwala et al, 2016, Cancer Genetics CrossRef
7. Selective Killing Effects of Cold Atmospheric Pressure Plasma with NO Induced Dysfunction of Epidermal Growth Factor Receptor in Oral Squamous Cell Carcinoma
   Jung-Hwan Lee et al, 2016, PLOS ONE CrossRef
8. Periostin derived from cancer-associated fibroblasts promotes esophageal squamous cell carcinoma progression via ADAM17 activation
   Yusuke Ishibashi et al, 2023, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
9. Advances and challenges in the treatment of esophageal cancer
   Shiming He et al, 2021, Acta Pharmaceutica Sinica B CrossRef
10. A mechanistic assessment of the nature of pharmacodynamic drug-drug interaction in vivo and in vitro
    Kuteesa R. Bisaso et al, 2023, In Silico Pharmacology CrossRef